Skip to main content
PMC home page
Thorax logoLink to Thorax
. 1984 Apr;39(4):299–304. doi: 10.1136/thx.39.4.299

Azlocillin compared with carbenicillin in the treatment of bronchopulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis.

A Penketh, M E Hodson, H Gaya, J C Batten
PMCID: PMC459787  PMID: 6426075

Abstract

A randomised controlled open comparison of azlocillin and gentamicin versus carbenicillin and gentamicin was carried out in patients with cystic fibrosis who were chronically infected with Pseudomonas aeruginosa. The clinical response was assessed by measurements of pulmonary function and of the patients' feelings of wellbeing scored on a visual analogue scale. The sputum penetration of the antibiotics used was also studied. The two groups of 10 patients were similar in terms of age, sex, and pulmonary function at entry to the trial. Both regimens produced significant improvement in pulmonary function over 10 days. The mean FEV1 in the azlocillin group increased from 1206 to 1760 ml (p less than 0.001). In the carbenicillin group the mean FEV1 increased from 1116 to 1619 ml (p less than 0.001). Significant improvements in peak expiratory flow rate, forced vital capacity, and score on the visual analogue scale were also seen but there was no significant difference between the antibiotic regimens. Despite high serum concentrations the sputum penetration of the antibiotics was poor.

Full text

PDF
299

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barnes P., Waterworth P. M. New cause of penicillin treatment failure. Br Med J. 1977 Apr 16;1(6067):991–993. doi: 10.1136/bmj.1.6067.991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bergan T., Michalsen H. Pharmacokinetics of azlocillin in children with cystic fibrosis. Arzneimittelforschung. 1979;29(12A):1955–1957. [PubMed] [Google Scholar]
  3. Daikos G. K., Giamarellou H., Hadjipolydorou K., Kanellakopoulou K. Pseudomonas infections of the lung treated with azlocillin. Microbiology, pharmacokinetics, clinic. Arzneimittelforschung. 1979;29(12A):1976–1978. [PubMed] [Google Scholar]
  4. Eykyn S. J. Azlocillin in the treatment of serious infection with Pseudomonas aeruginosa. J Antimicrob Chemother. 1982 May;9(5):395–403. doi: 10.1093/jac/9.5.395. [DOI] [PubMed] [Google Scholar]
  5. Kulczycki L. L., Murphy T. M., Bellanti J. A. Pseudomonas colonization in cystic fibrosis. A study of 160 patients. JAMA. 1978 Jul 7;240(1):30–34. [PubMed] [Google Scholar]
  6. König H. B., Metzger K. G., Mürmann R. P., Offe H. A., Schacht P., Schröck W. Azlocillin-ein neues Penicillin gegen Pseudomonas aeruginosa und andere gramnegative Bakterien. Infection. 1977;5(3):170–182. doi: 10.1007/BF01639754. [DOI] [PubMed] [Google Scholar]
  7. Lode H., Niestrath U., Koeppe P., Langmaack H. Azlocillin und Mezlocillin: Zwei neue semisynthetische Acylureidopenicilline. Infection. 1977;5(3):163–169. doi: 10.1007/BF01639753. [DOI] [PubMed] [Google Scholar]
  8. Marks M. I. The pathogenesis and treatment of pulmonary infections in patients with cystic fibrosis. J Pediatr. 1981 Feb;98(2):173–179. doi: 10.1016/s0022-3476(81)80631-2. [DOI] [PubMed] [Google Scholar]
  9. McCarthy M. M., Rourk M. H., Spock A. Bacteremia in patients with cystic fibrosis. Clin Pediatr (Phila) 1980 Nov;19(11):746–748. doi: 10.1177/000992288001901106. [DOI] [PubMed] [Google Scholar]
  10. Møller N. E., Eriksen K. R., Feddersen C., Flensborg E. W., Høiby N., Norn S., Rosendal K., Schiøtz P. O., Skov P. S. Chemotherapy against Pseudomonas aeruginosa in cystic fibrosis. A study of carbenicillin, azlocillin or piperacillin in combination with tobramycin. Eur J Respir Dis. 1982 Mar;63(2):130–139. [PubMed] [Google Scholar]
  11. Penketh A. R., Hodson M. E., Batten J. C. Ticarcillin compared with carbenicillin in the treatment of exacerbations of bronchopulmonary infection in cystic fibrosis. Br J Dis Chest. 1983 Apr;77(2):179–184. doi: 10.1016/0007-0971(83)90025-6. [DOI] [PubMed] [Google Scholar]
  12. Pitcher-Wilmott R. W., Levinsky R. J., Gordon I., Turner M. W., Matthew D. J. Pseudomonas infection, allergy, and cystic fibrosis. Arch Dis Child. 1982 Aug;57(8):582–586. doi: 10.1136/adc.57.8.582. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Prince A. S., Neu H. C. Activities of new beta-lactam antibiotics against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. Antimicrob Agents Chemother. 1981 Oct;20(4):545–546. doi: 10.1128/aac.20.4.545. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. SHWACHMAN H., KULCZYCKI L. L. Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period. AMA J Dis Child. 1958 Jul;96(1):6–15. doi: 10.1001/archpedi.1958.02060060008002. [DOI] [PubMed] [Google Scholar]
  15. Wise R., Gillett A. P., Andrews J. M., Bedford K. A. Activity of azlocillin and mezlocillin against gram-negative organisms: comparison with other penicillins. Antimicrob Agents Chemother. 1978 Apr;13(4):559–565. doi: 10.1128/aac.13.4.559. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. di Sant'agnese P. A., Davis P. B. Cystic fibrosis in adults. 75 cases and a review of 232 cases in the literature. Am J Med. 1979 Jan;66(1):121–132. doi: 10.1016/0002-9343(79)90491-1. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES